NEW YORK – Multiomics company Pleno said Thursday that it has a closed a $25 million Series B funding round.

纽约——多元经济体公司普莱诺（Pleno）周四表示，已完成2500万美元的B轮融资。

The company said it plans to use the funds to scale the development and commercialization of its RAPTOR multiomics platform.

该公司表示，计划利用这些资金扩大其猛禽多组学平台的开发和商业化。

The round included investment from Deerfield Management, Foresite Capital, and Medical Excellence Capital.

本轮投资包括Deerfield Management、Foresite Capital和Medical Excellence Capital的投资。

Pleno also announced that it has appointed Vik Vaz as its new CEO and member of its board of directors, effective immediately. Vaz was previously head of strategy and market intelligence and a leader of the companion diagnostics business at Illumina. Prior to that he worked as a partner at the Boston Consulting Group and McKinsey and Company.

普莱诺还宣布，已任命维克·瓦兹为其新任首席执行官和董事会成员，立即生效。。在此之前，他曾在波士顿咨询集团（Boston Consulting Group）和麦肯锡公司（McKinsey and Company）担任合伙人。

He replaces former CEO and founder Pieter van Rooyen..

他取代了前首席执行官兼创始人彼得·范鲁恩。。

Pleno's RAPTOR platform allows the targeted measurement of large numbers of nucleic acids and is intended as a more streamlined, less expensive, and higher-throughput alternative to next-generation sequencing in applications requiring analysis of large numbers of known nucleic acid targets. Based on so-called Hypercoding technology, the platform will be capable of detecting up to 10,000 nucleic acid targets per sample and processing up to 10,000 samples per day, Pleno has said..

Pleno的RAPTOR平台可以对大量核酸进行有针对性的测量，并且在需要分析大量已知核酸靶标的应用中，它可以作为下一代测序的更简化，更便宜和更高通量的替代方案。普莱诺表示，基于所谓的超编码技术，该平台将能够检测每个样本多达10000个核酸靶标，每天处理多达10000个样本。。

The Series B round follows a $40 million Series A round the company closed in 2022.

在B轮融资之前，该公司于2022年完成了价值4000万美元的a轮融资。